This article features some of the companies whose plant scientists are racing to unlock the medical benefits of the cannabis plant family as featured in this image.
GW Pharmaceuticals experts ran clinical trials on cbd as a treatment for two rare forms of epilepsy and received approval from the Food and Drug Administration (FDA). The drug is sold under the brand name Epidiolex.
Now, Epidiolex got approved more quickly than usual because the diseases it was being used to treat were very rare – but this was very intensive research nonetheless.
Another company, InMed Pharmaceuticals (OTC: IMLFF), is testing another cannabinoid – cannabinol (CBN) – to treat Epidermolysis Bullosa. It is also testing this same molecule as a treatment for glaucoma in pre-clinical, non-human studies.
Yet another company, Tilray Inc. (Nasdaq: TLRY), is supporting clinical studies being conducted at the McGill University health Centre in Quebec. Its cbd and thc capsules will be used to study how well medical cannabis can boost the immune systems of people living with human immunodeficiency virus (HIV).
As one last example, Aurora cannabis Inc. (NYSE: ACB) has partnered with the Ultimate Fighting Championship (UFC) to research the impact that cbd can have on athletes’ performance and ability to recover.
The research is being led by Jason Dyck, Ph.D. at the University of Alberta, and Duncan French, Ph.D., at the UFC Performance Institute.
These examples just barely scratch the surface of everything that’s going on. Information is also being collected from doctors prescribing cannabis to medical cannabis patients – providing rich fields of data from which further insights and discoveries can be gleaned.
Cannabis research is well underway alongside the growing public demand for an individual’s right to access and benefit from it.